Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Val Gebski

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8748-1844; OpenAlex author ID A5023743013. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 11

  1. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  2. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  3. C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1111/ajco.13993↗
  4. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001↗
  5. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  6. Computed Tomography Radiomics Signatures: Sensitive biomarkers for clinical decision support in pancreatic cancer- a pilot study Co-author DOI 10.1101/2021.12.03.21267217↗
  7. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  8. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk an… Co-author DOI 10.1186/s12885-021-08666-y↗
  9. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Co-author DOI 10.3389/fonc.2021.770022↗
  10. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Co-author DOI 10.1002/bjs.9892↗
  11. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the trea… Last author DOI 10.1038/bjc.2011.526↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Goldstein · 10 shared papers, 2012–2026 · strength 1.23
  2. Koroush Shahsavar Haghighi · 5 shared papers, 2021–2026 · strength 0.72
  3. Anthony James Gill · 5 shared papers, 2015–2026 · strength 0.64
  4. Joshua A. McCarroll · 4 shared papers, 2021–2026 · strength 0.59
  5. Amber L. Johns · 4 shared papers, 2021–2026 · strength 0.59
  6. Mert Erkan · 4 shared papers, 2021–2026 · strength 0.59
  7. Phoebe A. Phillips · 4 shared papers, 2021–2026 · strength 0.59
  8. George Sharbeen · 4 shared papers, 2021–2026 · strength 0.59
  9. John Kokkinos · 4 shared papers, 2021–2026 · strength 0.59
  10. Jennifer P. Morton · 4 shared papers, 2021–2026 · strength 0.59
  11. Andrew P. Barbour · 4 shared papers, 2015–2025 · strength 0.49
  12. Marina Pajic · 3 shared papers, 2021–2026 · strength 0.39
  13. Minoti Vivek Apte · 2 shared papers, 2021–2026 · strength 0.29
  14. Paul Timpson · 2 shared papers, 2021–2026 · strength 0.29
  15. Jaswinder Singh Samra · 3 shared papers, 2015–2021 · strength 0.28
  16. James G. Kench · 2 shared papers, 2015–2025 · strength 0.26
  17. Marion Harris · 2 shared papers, 2021–2023 · strength 0.25
  18. Lorraine A. Chantrill · 2 shared papers, 2021–2023 · strength 0.23
  19. Vanessa Bonazzi · 1 shared paper, 2025 · strength 0.21
  20. Kendelle Joan Murphy · 1 shared paper, 2026 · strength 0.21
  21. Australian Pancreatic Cancer Genome Initiative · 1 shared paper, 2026 · strength 0.20
  22. Abbas Habibalahi · 1 shared paper, 2021 · strength 0.13
  23. Ewa Magdalena Goldys · 1 shared paper, 2021 · strength 0.13
  24. Andrew Peter Dean · 1 shared paper, 2023 · strength 0.12
  25. Joanna Lee · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.